1. Home
  2. THH vs NCEL Comparison

THH vs NCEL Comparison

Compare THH & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TryHard Holdings Limited Ordinary Shares

THH

TryHard Holdings Limited Ordinary Shares

SELL

Current Price

$0.21

Market Cap

15.6M

Sector

N/A

ML Signal

SELL

NCEL

NewcelX Ltd. Ordinary Shares

SELL

Current Price

$3.76

Market Cap

22.0M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
THH
NCEL
Founded
2013
2008
Country
Japan
Switzerland
Employees
116
4
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.6M
22.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
THH
NCEL
Price
$0.21
$3.76
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
124.8K
33.2K
Earning Date
05-19-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$305.05
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.20
$1.83
52 Week High
$56.26
$5.12

Technical Indicators

Market Signals
Indicator
THH
NCEL
Relative Strength Index (RSI) 27.51 46.33
Support Level N/A $2.58
Resistance Level $0.53 $3.70
Average True Range (ATR) 0.02 0.34
MACD -0.00 -0.06
Stochastic Oscillator 4.47 0.00

Price Performance

Historical Comparison
THH
NCEL

About THH TryHard Holdings Limited Ordinary Shares

Tryhard Holdings Ltd is a Japan-based lifestyle entertainment company offering services across the entertainment and hospitality sectors. Its main businesses include event curation, consultancy and management, sub-leasing of venues, and restaurant operations. The company operates through four segments, with the majority of revenue generated from consultancy and management, which provides club planning, operations, event production, entertainer bookings, and sponsorship services. The event curation segment produces both in-house and client events; the sub-leasing segment rents venues and sub-leases them to clubs; and the restaurants segment operates themed dining outlets that complement its entertainment offerings.

About NCEL NewcelX Ltd. Ordinary Shares

NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.

Share on Social Networks: